Tenax Therapeutics (NASDAQ:TENX – Get Free Report) and Cue Biopharma (NASDAQ:CUE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.
Analyst Recommendations
This is a summary of recent ratings and price targets for Tenax Therapeutics and Cue Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tenax Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
| Cue Biopharma | 1 | 0 | 0 | 0 | 1.00 |
Tenax Therapeutics currently has a consensus price target of $39.67, indicating a potential upside of 245.53%. Given Tenax Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Cue Biopharma.
Insider and Institutional Ownership
Volatility and Risk
Tenax Therapeutics has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500.
Valuation and Earnings
This table compares Tenax Therapeutics and Cue Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tenax Therapeutics | N/A | N/A | -$52.60 million | ($1.40) | -8.20 |
| Cue Biopharma | $32.73 million | 3.15 | -$26.60 million | ($5.58) | -4.40 |
Cue Biopharma has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Tenax Therapeutics and Cue Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tenax Therapeutics | N/A | -56.32% | -53.12% |
| Cue Biopharma | -59.65% | -98.30% | -53.69% |
Summary
Tenax Therapeutics beats Cue Biopharma on 8 of the 14 factors compared between the two stocks.
About Tenax Therapeutics
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
